Novel Resistance Mutations to ALK Tyrosine Kinase Inhibition Arising During Cell-Culture Drug Selections in T-Cell Lymphoma

被引：0
|
作者：
Groysman, Matthew [1 ]
Amin, Amit Dipak [1 ]
Tapia, Edgar [1 ]
Rajan, Soumya [1 ]
Schatz, Jonathan [1 ]
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA
来源：
FASEB JOURNAL | 2015年 / 29卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
576.1
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Trka, a Novel Binding Partner of NPM-ALK Oncogenic Tyrosine Kinase, Facilitates the Survival of T-Cell Anaplastic Large-Cell Lymphoma
    Shi, Wenyu
    George, Suraj Konnath
    Curry, Choladda V.
    Alkan, Serhan
    Amin, Hesham M.
    BLOOD, 2014, 124 (21)
  • [2] Anaplastic lymphoma kinase (ALK): An important predictor of survival in peripheral T-cell lymphoma
    Aoun, P
    Greiner, T
    Vose, J
    Gordon, B
    Kollath, J
    Morris, S
    Chan, W
    Weisenburger, D
    MODERN PATHOLOGY, 1998, 11 (01) : 125A - 125A
  • [3] Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
    Martina Magni
    Giulia Biancon
    Sara Rizzitano
    Alessandra Cavanè
    Chiara Paolizzi
    Matteo Dugo
    Paolo Corradini
    Cristiana Carniti
    British Journal of Cancer, 2019, 121 : 567 - 577
  • [4] Tyrosine kinase inhibition to improve anthracycline-based chemotherapy efficacy in T-cell lymphoma
    Magni, Martina
    Biancon, Giulia
    Rizzitano, Sara
    Cavane, Alessandra
    Paolizzi, Chiara
    Dugo, Matteo
    Corradini, Paolo
    Carniti, Cristiana
    BRITISH JOURNAL OF CANCER, 2019, 121 (07) : 567 - 577
  • [5] RESISTANCE TO ANAPLASTIC LYMPHOMA KINASE (ALK) TYROSINE KINASE INHIBITORS (TKIs) IN PAEDIATRIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL)
    Hare, L.
    Prokoph, N.
    Burke, A.
    Turner, S.
    LEUKEMIA RESEARCH, 2022, 121 : S14 - S16
  • [6] FER and FES tyrosine kinase fusions in follicular T-cell lymphoma
    Debackere, Koen
    van der Krogt, Jo-Anne
    Tousseyn, Thomas
    Ferreiro, Julio Antonio Finalet
    Van Roosbroeck, Katrien
    Marcelis, Lukas
    Graux, Carlos
    Dierickx, Daan
    Ameye, Genevieve
    Vandenberghe, Peter
    Michaux, Lucienne
    Cools, Jan
    Wlodarska, Iwona
    BLOOD, 2020, 135 (08) : 584 - 588
  • [7] The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
    Rajan, Soumya S.
    Amin, Amit Dipak
    Li, Lingxiao
    Rolland, Delphine C.
    Li, Haiquan
    Kwon, Deukwoo
    Kweh, Mercedes F.
    Arumov, Artavazd
    Roberts, Evan R.
    Yan, Aimin
    Basrur, Venkatesha
    Elenitoba-Johnson, Kojo S. J.
    Chen, Xi Steven
    Puvvada, Soham D.
    Lussier, Yves A.
    Bilbao, Daniel
    Lim, Megan S.
    Schatz, Jonathan H.
    ONCOGENE, 2020, 39 (10) : 2103 - 2117
  • [8] The mechanism of cancer drug addiction in ALK-positive T-Cell lymphoma
    Soumya S. Rajan
    Amit Dipak Amin
    Lingxiao Li
    Delphine C. Rolland
    Haiquan Li
    Deukwoo Kwon
    Mercedes F. Kweh
    Artavazd Arumov
    Evan R. Roberts
    Aimin Yan
    Venkatesha Basrur
    Kojo S. J. Elenitoba-Johnson
    Xi Steven Chen
    Soham D. Puvvada
    Yves A. Lussier
    Daniel Bilbao
    Megan S. Lim
    Jonathan H. Schatz
    Oncogene, 2020, 39 : 2103 - 2117
  • [9] ALK Kinase Domain Mutations in Primary Anaplastic Large Cell Lymphoma: Consequences on NPM-ALK Activity and Sensitivity to Tyrosine Kinase Inhibitors
    Lovisa, Federica
    Cozza, Giorgio
    Cristiani, Andrea
    Cuzzolin, Alberto
    Albiero, Alessandro
    Mussolin, Lara
    Pillon, Marta
    Moro, Stefano
    Basso, Giuseppe
    Rosolen, Angelo
    Bonvini, Paolo
    PLOS ONE, 2015, 10 (04):
  • [10] IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells
    Shi, Ping
    Lai, Raymond
    Lin, Quan
    Iqbal, Abid S.
    Young, Leah C.
    Kwak, Larry W.
    Ford, Richard J.
    Amin, Hesham M.
    BLOOD, 2009, 114 (02) : 360 - 370
12345